Clinical trials: flow cytometry
Kidney Cancer, Melanoma (Skin)
Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00617799
- Testing
- aldesleukin, gene expression analysis, mutation analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Leukemia, Lymphoblastic
"Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
It is a multicenter, non-interventional, non pharmacological, translational, prospective study. Any decision about drug administration is made by the physician based on his clinical judgment in the context of clinical practice…
- Trial name
- TRINEG-ALL (NCT06919393)
- Testing
- "Triple negative" adul B-cell ALL
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Renal Cell Cancer, Stage IV Renal Cell Cancer
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Recombinant interferon alfa-2b may interfere with the growth of cancer cells and slow the growth of kidney cancer.
- Trial name
- NCT01158534
- Testing
- celecoxib, recombinant interferon alfa-2b, polymerase chain reaction
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Trial name
- NCT00658892
- Testing
- B7-DC cross-linking antibody rHIgM12B7, flow cytometry, immunologic technique
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Breast Cancer
Identifying Circulating Breast Cancer Cells in Women With Metastatic Breast Cancer
RATIONALE: Studying samples of blood and pleural or peritoneal fluid from patients with metastatic breast cancer in the laboratory may help doctors identify biomarkers related to breast cancer and learn more about how breast…
- Trial name
- NCT00897338
- Testing
- flow cytometry, fluorescence activated cell sorting, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer, Inflammatory Breast Cancer
MUC1 Vaccine for Triple-negative Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
- Conditions
- Breast Cancer, Inflammatory Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00986609
- Testing
- MUC-1 peptide vaccine, poly ICLC, MUC1 peptide-poly-ICLC adjuvant vaccine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Joseph Baar, MD, PhD
Lung Cancer, Surgery
Expression of the Inhibitory Receptors on Lymphocytes T Cells After Lung Cancer Surgery.
Postoperative pneumonia is one of the most common complications after lung cancer surgery and associated with a morbidity and mortality.
- Trial name
- POIR (NCT03549546)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Leukemia
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01232842
- Testing
- cytogenetic analysis, HUMARA assay, fluorescence activated cell sorting
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Asthma, Eosinophilic Asthma
Effect of Mepolizumab on Severe Eosinophilic Asthma
Two parts: A:Case-control study including 15 healthy adult donors and 15 severe adult eosinophilic asthmatics selected for treatment with mepolizumab.
- Trial name
- EMESEA (NCT04641741)
- Testing
- Mepolizumab 100 MG
- Where
- 5 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario de Santiago
B-cell Acute Lymphocytic Leukemia
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
This study will evaluates the safety and efficacy of Chimeric antigen receptor T cells (CAR-T) in treating central nervous system B-cell acute lymphocytic leukemia.
- Trial name
- NCT03064269
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Pregnancy Complicated by Low Implantation
Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial
Both organ-specific and systemic autoimmunity are associated with an increased prevalence of recurrent miscarriage and reproductive failure, rendering the role of the maternal immunological system in fertility a key concept.
- Trial name
- ILRIFRM (NCT01679561)
- Testing
- intralipid
- Where
- Egypt
- Volunteers
- healthy volunteers welcome
- Sponsor
- Woman's Health University Hospital, Egypt
Brain and Central Nervous System Tumors
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00621686
- Testing
- bevacizumab, sorafenib tosylate
- Where
- 204 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Leukemia, Myeloid, Acute
Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as Surrogate Endpoint for Survival
Objectives To demonstrate that measurable residual disease assessed by multiparameter flow cytometry during intensive treatment is a surrogate for overall survival and thus an early read-out for drug efficacy Study design…
- Trial name
- PERDAM (NCT03549351)
- Testing
- Measurable residual disease measured by flow cytometry
- Where
- Germany
- Volunteers
- 51 people
- Sponsor
- University Hospital Heidelberg
Hematologic Malignancy, Hematologic Neoplasms
Evaluation of ClearLLab LS Screening Panel
This is a multi-center study to evaluate the clinical performance of ClearLLab LS screening panel with specimens from subjects for the diagnosis of hematologic malignancies.
- Conditions
- Hematologic Malignancy, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05819762
- Testing
- Flow Cytometry
- Where
- 4 sites in China
- Volunteers
- 831 people
- Sponsor
- Beckman Coulter, Inc.
Ependymoma
Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod
The purpose of this study is to see if vaccination with HLA-A2 restricted peptides, combined with the immunoadjuvant imiquimod is safe and can induce immune responses in children with recurrent ependymomas.
- Trial name
- NCT01795313
- Testing
- HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- James Felker
Myeloid Proliferations Associated With Down Syndrome
Study of Blood Samples From Newborns With Down Syndrome
This research study is looking at blood samples from newborns with Down syndrome. Studying the genes expressed in samples of blood from patients with Down syndrome may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00959283
- Testing
- Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 189 sites in United States, Australia and 2 more
- Volunteers
- 180 people
- Sponsor
- Children's Oncology Group
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute
Lymphoma
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00363090
- Testing
- alemtuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
DNA Damage, Granulosa Cells
Predictive Value of Granulosa Cell DNA Damage in the Success of Assisted Reproductive Technique
Deoxyribonucleic acid (DNA) damage of granulosa cells obtained during oocyte retrieval will be evaluated by flow cytometry with detection of Histone H2A.X and Phosphorylated Gamma H2A.X protein levels in patients with low ovarian…
- Trial name
- NCT05558046
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Zeynep Kamil Maternity and Pediatric Research and Training Hospital
Prostatic Neoplasms
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
This is a Phase II study of docetaxel, bevacizumab, prednisone and thalidomide in patients with androgen independent metastatic prostate cancer who are previously untreated with chemotherapy.
- Trial name
- NCT00089609
- Testing
- Docetaxel, Thalidomide, Prednisone
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)